arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CV Sciences, Inc.

CVSI
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

CV Sciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth -17.5% ↘
Op. Margin -10.1% →
ROIC -19.3% ↗
FCF / Share $0.00 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity 0.00
info Valuation on last close.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.98M
↓ -17.5% —
Net Income Profit after all expenses
$-643.00K
↓ -489.9% —
Operating Margin Operating profit as % of sales
-10.1%
↓ -1.3% 22th
FCF / Share Free cash flow per share
$0.00
↓ -87.9% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
20
Returns ↓
13
Financial Health ↑
20
Cash Quality ↑
42

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 65 quarters